These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan. Francis JH; Abramson DH; Gaillard MC; Marr BP; Beck-Popovic M; Munier FL Ophthalmology; 2015 Jun; 122(6):1173-9. PubMed ID: 25795478 [TBL] [Abstract][Full Text] [Related]
9. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Ghassemi F; Shields CL Arch Ophthalmol; 2012 Oct; 130(10):1268-71. PubMed ID: 23044940 [TBL] [Abstract][Full Text] [Related]
10. Diffuse chorioretinal atrophy after a single standard low- dose intravitreal melphalan injection in a child with retinoblastoma: a case report. Chao A; Kao LY; Liu L; Wang NK BMC Ophthalmol; 2016 Mar; 16():27. PubMed ID: 26975871 [TBL] [Abstract][Full Text] [Related]
11. Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma. Ghassemi F; Shields CL; Ghadimi H; Khodabandeh A; Roohipoor R JAMA Ophthalmol; 2014 Aug; 132(8):936-41. PubMed ID: 24789622 [TBL] [Abstract][Full Text] [Related]
12. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Munier FL; Gaillard MC; Balmer A; Soliman S; Podilsky G; Moulin AP; Beck-Popovic M Br J Ophthalmol; 2012 Aug; 96(8):1078-83. PubMed ID: 22694968 [TBL] [Abstract][Full Text] [Related]
13. Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma Model. Kaczmarek JV; Bogan CM; Pierce JM; Tao YK; Chen SC; Liu Q; Liu X; Boyd KL; Calcutt MW; Bridges TM; Lindsley CW; Friedman DL; Richmond A; Daniels AB Invest Ophthalmol Vis Sci; 2021 Nov; 62(14):8. PubMed ID: 34757417 [TBL] [Abstract][Full Text] [Related]
14. Not All Seeds Are Created Equal: Seed Classification Is Predictive of Outcomes in Retinoblastoma. Berry JL; Bechtold M; Shah S; Zolfaghari E; Reid M; Jubran R; Kim JW Ophthalmology; 2017 Dec; 124(12):1817-1825. PubMed ID: 28655537 [TBL] [Abstract][Full Text] [Related]
16. INTRAVITREOUS CHEMOTHERAPY FOR ACTIVE VITREOUS SEEDING FROM RETINOBLASTOMA: Outcomes After 192 Consecutive Injections. The 2015 Howard Naquin Lecture. Shields CL; Douglass AM; Beggache M; Say EA; Shields JA Retina; 2016 Jun; 36(6):1184-90. PubMed ID: 26630319 [TBL] [Abstract][Full Text] [Related]
17. TOXICITY AND EFFICACY OF INTRAVITREAL MELPHALAN FOR RETINOBLASTOMA: 25 µg Versus 30 µg. Liao A; Hsieh T; Francis JH; Lavery JA; Mauguen A; Brodie SE; Abramson DH Retina; 2021 Jan; 41(1):208-212. PubMed ID: 32106160 [TBL] [Abstract][Full Text] [Related]
18. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Abramson DH; Dunkel IJ; Brodie SE; Kim JW; Gobin YP Ophthalmology; 2008 Aug; 115(8):1398-404, 1404.e1. PubMed ID: 18342944 [TBL] [Abstract][Full Text] [Related]
19. Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients. Xue K; Ren H; Meng F; Zhang R; Qian J BMC Ophthalmol; 2019 Feb; 19(1):61. PubMed ID: 30808420 [TBL] [Abstract][Full Text] [Related]
20. INTRAVITREAL MELPHALAN AS SALVAGE THERAPY FOR REFRACTORY RETINAL AND SUBRETINAL RETINOBLASTOMA. Francis JH; Marr BP; Brodie SE; Gobin P; Dunkel IJ; Abramson DH Retin Cases Brief Rep; 2016; 10(4):357-60. PubMed ID: 26630243 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]